Mr. Piper brings more than 25 years of experience in corporate healthcare finance and has a successful track-record guiding biotechnology companies through significant organizational growth.Prior to joining Scorpion Therapeutics, he…
Mr. Piper brings more than 25 years of experience in corporate healthcare finance and has a successful track-record guiding biotechnology companies through significant organizational growth.
Prior to joining Scorpion Therapeutics, he served as Chief Financial Officer at Prelude Therapeutics, where he established the finance function and helped lead the company to a successful initial public offering in 2020. Prior to Prelude, he served as Chief Financial Officer and Corporate Secretary at Aevi Genomic Medicine (later acquired by Cerecor, Inc.). Mr. Piper served as Vice President, Finance and Investor Relations at Medgenics, Inc. from 2014 to 2016, and prior to Medgenics, he had a 13-year career at Shire Pharmaceuticals (later acquired by Takeda Pharmaceutical Company Limited). Mr. Piper held key roles in Investor Relations, Corporate Venture Capital, and numerous additional financial roles, including two years spent in Dublin, Ireland establishing Shire’s geographic expansion strategies.
Brian received his B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.